|Gemphire Therapeutics, Inc. at H.C. Wainwright 2nd Annual NASH Investor Conference (Replay)03/19/18 at 8:40 a.m. ET|
Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>
NASDAQ | GEMP (Common Stock)
03/20/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Press Releases More
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results03/15/18
Gemphire Therapeutics to Announce Fourth Quarter and Year End 2017 Financial Results on Thursday, March 1503/13/18
Gemphire to Present at Two Investor Conferences03/08/18
Investor Events More
There are currently no events scheduled.